PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions

Arbutus Biopharma Corporation (ABUS)

Equity · Currency in USD · Last updated Dec 2, 2023
SummaryFinancials

Company Info

ISINCA03879J1003
CUSIP03879J100
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$342.10M
EPS-$0.46
Revenue (TTM)$22.24M
Gross Profit (TTM)-$45.39M
EBITDA (TTM)-$77.12M
Year Range$1.69 - $3.15
Target Price$4.60
Short %5.34%
Short Ratio11.95

Share Price Chart


Loading data...

Performance

The chart shows the growth of an initial investment of $10,000 in Arbutus Biopharma Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%0.00%100.00%200.00%300.00%JulyAugustSeptemberOctoberNovemberDecember
-71.16%
291.97%
ABUS (Arbutus Biopharma Corporation)
Benchmark (^GSPC)

S&P 500

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ABUS

Arbutus Biopharma Corporation

Return

Arbutus Biopharma Corporation had a return of -12.88% year-to-date (YTD) and -12.88% in the last 12 months. Over the past 10 years, Arbutus Biopharma Corporation had an annualized return of -13.25%, while the S&P 500 had an annualized return of 9.87%, indicating that Arbutus Biopharma Corporation did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date-12.88%19.67%
1 month10.33%8.42%
6 months-21.32%7.29%
1 year-12.88%12.71%
5 years (annualized)-14.20%10.75%
10 years (annualized)-13.25%9.87%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2023-0.80%-7.63%-5.65%-6.45%-0.00%-9.85%12.02%

Risk-Adjusted Performance

This table presents a comparison of risk-adjusted performance metrics for Arbutus Biopharma Corporation (ABUS) and S&P 500 (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
ABUS
Arbutus Biopharma Corporation
-0.32
^GSPC
S&P 500
0.91

Sharpe Ratio

The current Arbutus Biopharma Corporation Sharpe ratio is -0.32. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.00JulyAugustSeptemberOctoberNovemberDecember
-0.32
0.91
ABUS (Arbutus Biopharma Corporation)
Benchmark (^GSPC)

Dividend History


Arbutus Biopharma Corporation doesn't pay dividends

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%JulyAugustSeptemberOctoberNovemberDecember
-93.44%
-4.21%
ABUS (Arbutus Biopharma Corporation)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Arbutus Biopharma Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Arbutus Biopharma Corporation was 97.19%, occurring on Oct 9, 2019. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-97.19%Mar 12, 20141406Oct 9, 2019
-80.95%Jan 20, 2011213Nov 25, 2011457Sep 26, 2013670
-36.08%Nov 16, 201024Dec 20, 201020Jan 19, 201144
-31.5%Oct 8, 201346Dec 11, 201321Jan 13, 201467
-18.01%Feb 26, 20144Mar 3, 20142Mar 5, 20146

Volatility Chart

The current Arbutus Biopharma Corporation volatility is 13.19%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%14.00%JulyAugustSeptemberOctoberNovemberDecember
13.19%
2.79%
ABUS (Arbutus Biopharma Corporation)
Benchmark (^GSPC)